» Articles » PMID: 39272940

Cisplatin Resistance and Metabolism: Simplification of Complexity

Overview
Journal Cancers (Basel)
Publisher MDPI
Specialty Oncology
Date 2024 Sep 14
PMID 39272940
Authors
Affiliations
Soon will be listed here.
Abstract

Cisplatin is one of the most well-known anti-cancer drugs and has demonstrated efficacy against numerous tumor types for many decades. However, a key challenge with cisplatin, as with any chemotherapeutic agent, is the development of resistance with a resultant loss of efficacy. This resistance is often associated with metabolic alterations that allow insensitive cells to divide and survive under treatment. These adaptations could vary greatly among different tumor types and may seem questionable and incomprehensible at first glance. Here we discuss the disturbances in glucose, lipid, and amino acid metabolism in cisplatin-resistant cells as well as the roles of ferroptosis and autophagy in acquiring this type of drug intolerance.

References
1.
Hussain S, Singh A, Nazir S, Tulsyan S, Khan A, Kumar R . Cancer drug resistance: A fleet to conquer. J Cell Biochem. 2019; 120(9):14213-14225. DOI: 10.1002/jcb.28782. View

2.
Zhang X, Zhang M, Cong Q, Zhang M, Zhang M, Lu Y . Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy. Int J Biochem Cell Biol. 2017; 95:9-16. DOI: 10.1016/j.biocel.2017.12.010. View

3.
Lopez-Portugues C, Montes-Bayon M, Diez P . Biomarkers in Ovarian Cancer: Towards Personalized Medicine. Proteomes. 2024; 12(1). PMC: 10974094. DOI: 10.3390/proteomes12010008. View

4.
Bedi M, Ray M, Ghosh A . Active mitochondrial respiration in cancer: a target for the drug. Mol Cell Biochem. 2021; 477(2):345-361. DOI: 10.1007/s11010-021-04281-4. View

5.
Warburg O, Wind F, Negelein E . THE METABOLISM OF TUMORS IN THE BODY. J Gen Physiol. 2009; 8(6):519-30. PMC: 2140820. DOI: 10.1085/jgp.8.6.519. View